We have expressed P-glycoprotein (P-gp) encoded by the mouse mdr3 gene in the yeast Saccharomyces cerevisiae and have developed an experimental protocol to isolate and purify inside-out plasma membrane vesicles (IOVs) from these ceUls. Biochemical characterization of IOVs from control and P-gp-expressing cels isolated by this procedure show that they are greatly enriched for plasma membrane markers, are tightly sealed, and are competent for D-glucose transport. P-gp expression in these vesicles results in the appearance of a specific ATP-dependent and temperaturesensitive transport of the drugs colchicine and vinblastine that is osmotically sensitive. P-gp-mediated drug transport into these IOVs is inhibited by a known P-gp modulator, verapamil, and can be abrogated by prior incubation of the IOVs with an anti-P-gp antibody. A Ser-939 --Phe mutation within the predicted transmembrane domain 11 of P-gp, which is known to modulate its function in mammalian cells, drastically reduces drug transport in IOVs obtained from yeast cells expressing the mutant protein. The successful demonstration of active drug transport into IOVs from P-gp-expressing yeast cells indicates that P-gp can mediate both chemotherapeutic drugs and a-pheromone transport in yeast cells.
predicted transmembrane domain 11 of P-gp, which is known to modulate its function in mammalian cells, drastically reduces drug transport in IOVs obtained from yeast cells expressing the mutant protein. The successful demonstration of active drug transport into IOVs from P-gp-expressing yeast cells indicates that P-gp can mediate both chemotherapeutic drugs and a-pheromone transport in yeast cells.
Multidrug resistance (MDR) is caused in vitro and in vivo by overexpression of a membrane phosphoglycoprotein, P-glycoprotein (P-gp) (1) . P-gp is encoded by a small family of related mdr genes composed of three members in rodents (mdrl, mdr2, and mdr3) (2) (3) (4) and two in humans (MDR] and MDR2; now designated PGY1 and PGY2) (5, 6) . The prototype P-gp is formed by two homologous halves, each composed of six predicted transmembrane domains and one nucleotide-binding (NB) fold (7) . The P-gp family is also part of a very large family of ATP-binding cassette membrane transporters (8) with members in prokaryotes and lower and higher eukaryotes, including the yeast Saccharomyces cerevisiae a peptide pheromone transporter STE6 (9) .
The exact mechanism of P-gp action remains largely unsolved. A considerable body of evidence suggests that P-gp acts as a membrane-bound, ATP-dependent drug efflux pump that reduces intracellular drug accumulation in resistant cells. These include the observations that (i) P-gp expression in mdr transfectants causes both reduced accumulation and increased cellular efflux of MDR drugs, both of which are ATP dependent (1); (ii) P-gp binds photoactivatable ATP analogs (10) and shows ATPase activity (11) , and mutations in either of its two predicted NB sites abrogate function (12) ; (iii) P-gp binds photoactivatable drug analogs (13) , and mutations in its predicted transmembrane domains modulate substrate specificity and alter drug binding (14, 15) ; and (iv) P-gp shows structural and functional homology with a number of ATP-binding cassette transport proteins implicated in the transmembrane transport of structurally heterogeneous substrates, such as peptides, ions, sugars, and fatty acids
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. (16) . Recently, additional and/or alternative biological activities have been attributed to P-gp in drug-resistant cells, such as the osmotic-sensitive Cl-channel (17) , ATP carrier (18) , intracellular pH regulator (19) , and lipid flippase (20) . Purification and reconstitution of P-gp in proteolipososomes will be required to analyze these various transport activities and determine how they may contribute to P-gp-mediated drug resistance. Finally, the specific protein domains and amino acid residues involved in (i) recognition of structurally dissimilar substrates, (ii) signal transduction from the NB sites, (iii) and membrane helix packing all remain poorly identified. In the absence of three-dimensional protein structure information, an expression system allowing rapid and extensive genetic analysis of P-gp is needed to carry out structurefunction analysis of this protein.
Although the human MDR1 polypeptide has been successfully overexpressed in yeast cells, the consequences of this expression on drug resistance and/or drug transport in these cells remain unclear, causing either increased (21) (9) . To pursue the characterization of P-gp expressed in S. cerevisiae, an experimental protocol for isolating tightly sealed plasma membrane (PM) vesicles of inverted polarity has been elaborated. The effect of expressing wild-type or mutant P-gps on the kinetics of MDR drug accumulation in these vesicles has been analyzed. Analytical Methods. The ATPase activity in IOV and ghost fractions was measured as described elsewhere (23) . Membrane suspensions (0.3 mg/ml) in VB1 buffer were diluted with an equal volume of VB1 buffer containing 5 mM NaATP and 10 mM MgCl2 (omitted in the presence of EDTA) and incubated at 37°C for 20 min. The reactions were stopped by addition of ice-cold 1% SDS/2% H2SO4/0.5% ammonium molybdate, and 100-,ul aliquots (3-4 ,ug of protein) were added to 50 Al of 1% ascorbic acid and further incubated 30 min at 25°C. Optical density was determined at 660 nm using an ELISA reader (Bio-Rad). Protein concentrations were determined according to Bradford in the presence of 5% formic acid.
MATERIALS AND METHODS
RESULTS AND DISCUSSION Isolation and Characterization of IOVs. The primary goal of this study was to functionally express P-gp in yeast cells. For this, it was necessary to devise an experimental protocol to isolate IOVs where P-gp-mediated drug transport could be assayed. The procedure used is based on a method that was originally described to purify inverted PM vesicles from the eukaryote Neurospora crassa (24, 25) and that was previously adapted to isolate yeast PM fractions (26, 27) . The protocol involves coating the surface of yeast spheroplasts with Con A to stabilize the plasma membrane, preventing fragmentation and spontaneous revesiculation upon osmotic lysis of the cells. This treatment also allows physical separation of large lectin-coated membrane sheets (ghosts) from other cellular constituents by low-speed centrifugation. After removal of Con A with excess of a-methylmannoside, these open membrane sheets are then converted to closed vesicles, which can be recovered by isometric centrifugation. The resulting vesicles are finally subfractionated by affinity chromatography into inside-out and right-side-out vesicles.
Yeast strain JPY201 transformed either with control plasmid pVT or with the same plasmid carrying full-length cDNAs for the mouse mdr3 gene (mdr3S) or a mutant mdr3 gene (mdr3F) with reduced activity was used in all experiments. Starting with 2-3 g of yeast cells, we could routinely obtain 20-30 mg of the ghost fraction and 0.4-0.6 mg of the final vesicular fraction (8% and 0.4% ofthe starting material). Examination of the final membrane fraction by electron microscopy showed that it contained unilamellar vesicles with a mean diameter ranging from 1.5 to 3 ,um (data not shown). To showed similar amounts of a net Mg2+-dependent release of inorganic phosphate (Pi) (the calculated value of 128.2-138.8 nmol'mg-'*min-1 was set at 100%). Addition of vanadate completely abolished ATP hydrolysis (4-6%), with the amounts of Pi released (63 nmol mg-1 min-1) similar to background levels (60 nmol mg-1*min-1) measured in the negative controls in the absence of Mg2+ (+EDTA) or where ATP had been replaced by AMP (data not shown). The specific activity of this ATPase measured in our vesicle preparations is lower than the 250-700 milliunits/mg (1 unit = 1,umol ofPi released per min) value reported for whole PM preparations. This difference results from the higher pH (7.5) used in our ATPase measurements and subsequent drug transport assays (optimal pH for P-gp ATPase activity), at which the activity of the PM H+-ATPase is reduced by 60%o over its maximal activity measured at pH 6 (29) . Mg2+-dependent ATP hydrolysis was also measured in these vesicles in the presence of Biochemistry: Ruetz et al. Triton X-100 added to a final concentration of 0.05%. At this concentration, Triton X-100 only permeabilizes rather than solubilizes membrane vesicles, therefore permitting access to masked ATPases present in right-side-out oriented vesicles. This treatment had no effect on the overall ATPase activity ( Table 1 ), suggesting that the majority of the isolated vesicles were in the inverted orientation (IOVs).
Since vanadate is also a potent inhibitor of other ATPases as well as acid and alkaline phosphatases (29) , the effect of additional inhibitors of PM H+-ATPase was investigated. Both diethylstilbestrol (29) and miconazole nitrate (29) strongly inhibit ATP hydrolysis in these vesicles, causing a 75% and 85% reduction in Pi release (Table 1) , respectively.
In contrast, sodium azide, a specific inhibitor of the mitochondrial H+-ATPase, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, an inhibitor ofthe vacuolar H+-ATPase (29), do not affect the overall Mg2+-dependent ATP hydrolysis. These results indicate that the vesicle preparations contain PMs primarily and are significantly depleted of mitochondrial and vacuolar membranes. Finally, the effect of the inhibitors on ATPase activity was also tested in the ghost membrane fraction to deduce a relative enrichment factor for the three major ATPases. The final purification steps used to isolate the PM vesicle fraction resulted in a 6-to 7-fold enrichment in PMs with a combined residual mitochondrial and vacuolar contamination of <10%o (data not shown). A comparison of data obtained for pVT, mdr3F, and mdr3S indicates that the ATPase activity of P-gp could not be detected in our IOV preparations (Table 1) , even after treatment with VBL or verapamil (data not shown), both known modulators ofP-gp ATPase activity (30) . P-gp ATPase activity is possibly masked by the strong activity of the PM H+-ATPase.
The structural integrity of the isolated PM vesicles and their capacity to carry out transport were then tested. For this, we measured D-glucose influx/counterflow in vesicles from JPY201 cells transformed with either pVT, mdr3S, or mdr3F ( Fig. 1) (27) completely abolished at 00C. The counterflow is specific and is not observed when the vesicles are preloaded with L-glucose ( Fig. 1) (Fig. 2) . While little if any VBL accumulation is detected in control pVT IOVs, mdr3S IOVs accumulate VBL rapidly over the 10-min time course, with a maximal accumulation of5-to 6-fold above background (pVT control). The kinetics of COL transport in these vesicles are similar to those measured for VBL, with no accumulation in pVT IOVs and rapid accumulation in mdr3S IOVs, reaching a maximum 10-15 min after initiation of transport (10-fold increase above background). The Ser-939 --Phe substitution in P-gp TM 11 (mdr3F IOVs) causes 75% reduction in VBL accumulation and a complete abrogation of COL uptake in IOVs from mutant-expressing cells (Fig. 2) . The Fig. 3A, lowering the temperature from 37°C to 25°C results in a 50% reduction in the rate of VBL accumulation in the 1OVs. Reducing the assay temperature to 0°C completely abolished Fig. 2 at either0OC, 250C, or 3rC. (B) IOVs were initially resuspended in VB1 buffer containing increasing concentrations of sucrose (0.25-1 M). VBL uptake was measured at 1-, 2-, and 10-min intervals in TB1 buffer (370C) adjusted with identical concentrations of sucrose. drug accumulation into mdr3S IOVs. The results indicate that VBL transport is mediated by a temperature-dependent, carrier-mediated transport process. Second, we determined whether VBL accumulation in mdr3S IOVs is proportional to the intravesicular volume, which can be reduced by increasing the sucrose concentration outside the vesicles. Therefore, VBL transport was measured into mdr3S IOVs resuspended in VB buffer containing increasing concentrations of sucrose (Fig. 3B) . The results indicate that VBL uptake is inversely proportional to the sucrose concentration in the transport buffer and therefore to the intravesicular volume. At 1 M sucrose, no drug accumulation is detected over the 10-min incubation assay, with a final VBL uptake of 50-60 pmol/mg of protein. This value is similar to that measured in normal conditions in control pVT IOVs (Fig. 2) or in mdr3S IOVs treated with vanadate ( Fig. 2) and most likely represents initial nonspecific drug binding to the vesicles. Together, these data are compatible with osmotic sensitive drug accumulation in the intravesicular space of mdr3S IOVs. However, the high degree of hydrophobicity and high lipid partition coefficient of VBL (32) limit the interpretation of sensitivity of transport to osmolarity.
Effect of Inhibitors on P-gp-Mediated Drug Transport in Yeast IOVs. To further characterize the drug transport activity detected in mdr3S and mdr3F IOVs, the effect of several inhibitors on VBL transport was monitored (Fig. 4) . The effect of the protonophore carbonylcyanide m-chlorophenylhydrazone was first measured. IOVs contain significant amounts of the vanadate-sensitive PM H+-ATPase, which generates a proton electrochemical gradient (AS4H+, interior positive and/or acid) that could drive accumulation of MDR drugs (32) . The results shown in Fig. 4 clearly show that this is not the case, as carbonylcyanide m-chlorophenylhydrazone has no effect on VBL accumulation in mdr3S or mdr3F IOVs. In mammalian cells, P-gp-mediated drug resistance is strictly dependent on intact intracellular pools of nucleotide triphosphates (1) . Indeed, P-gp has two predicted NB sites, both of which are absolutely required for function (12) . Finally, the ATPase activity of P-gp also seems to be required for biological activity (12, 30) . Therefore, the requirement for ATP of the mdr3-induced VBL transport in 500, IOVs was investigated (Fig. 4) . Enhanced VBL accumulation in mdr3S IOVs is strictly ATP dependent and requires ATP hydrolysis since neither AMP (Fig. 4) nor the nonhydrolyzable ATP analogue adenosine 5'-[thio]triphosphate (data not shown) supports VBL transport. In addition, omission of the divalent cation Mg2+ from the transport buffer completely abolishes VBL transport into mdr3S IOVs. P-gp action can be inhibited by a series of structurally heterogeneous compounds such as verapamil, trifluoperazine, progesterone, cyclosporin A, and many others (33) . The possible modulatory effect ofone such agent, verapamil, was tested here (Fig.  4) . As shown, verapamil completely inhibits VBL accumulation into mdr3S IOVs. Finally, the effect of a specific anti-P-gp antibody on VBL transport into mdr3S IOVs was evaluated. Mouse anti-P-gp monoclonal antibody C219 recognizes the epitope VVQEALD, which is located immediately downstream of each of the two predicted NB sites of P-gp (34) . Structural predictions and epitope-mapping studies suggest that these sites are located on the intracellular face of the membrane of intact cells (16) . Therefore, in IOVs, these sites should be exposed to the outside and should be readily accessible to an antibody such as C219. Results in Fig. 4 show that preincubation of the mdr3S IOVs for 30 min at 25°C with C219 abolishes drug transport.
CONCLUSION
We have developed an experimental protocol for the isolation of yeast plasma membrane vesicles of inverted orientation containing functional P-gp. The system catalyzes ATPdependent, verapamil-sensitive drug transport with all the characteristics of P-gp-mediated drug transport in mammalian cells, including inhibition of transport by anti-Pgp antibodies. In addition, the modulatory effect of a single point mutation on mdr3 function (overall activity and substrate specificity) reported for intact mammalian cells (31) has been qualitatively and quantitatively reproduced in IOVs expressing the corresponding wild-type and mutant proteins. The results reflect proper membrane insertion and targeting of mammalian P-gp in yeast cells, leading to preservation of functional characteristics of P-gp-mediated drug transport in yeast IOVs. This functional expression system provides an ideal experimental tool for in-depth biochemical and pharmacological characterization of P-gp function. Specifically, the mechanism of P-gp action remains unknown and can only be solved by purification of P-gp to homogeneity, followed by reconstitution into lipid vesicles. Although recent attempts in this direction show promising results, they are hampered by the limited availability of starting material from either drugresistant cell lines (35) or insect cells overexpressing large amounts ofrecombinant protein (30, 36) . The yeast expression system described here should allow the rapid and simplified production of large amounts of biologically active P-gp, alleviating a key problem to purification and reconstitution. Recently, we have shown that the structural homology detected between mammalian P-gp and its yeast homolog STE6 translates into functional homology since mdr3S can complement a null allele at the STE6 locus (9) . In addition, we observed that transport ofthe a peptide pheromone by mdr3S in these cells is mechanistically similar to drug transport by mdr3S in mammalian cells, since the mdr3F mutant is inactive in the STE6 complementation assay. These data together with those reported here demonstrate that P-gp can transport both MDR drugs and the peptide pheromone a in yeast. The availability of a quick assay to monitor mdr3 complementation in haploid yeast cells (9) allows for rapid functional screening of P-gp mutants obtained by random or targeted mutagenesis and should also permit the production and characterization of intragenic suppressor mutations. The parallel effect of such mutations on P-gp-mediated drug transport can be readily established in IOVs. Therefore, the yeast model should greatly facilitate the structure-function analysis of P-gp by classical genetic means, a key experimental approach in the absence of three-dimensional structure. Finally, the model system described here should allow functional analysis of other members of the ABC superfamily of transport proteins, including CFTR (37), TAPl/ TAP2 (38) , and PMP70/ALDP (39) .
